Technology Transfer Office
Search

Mnemo Therapeutics

Institut Curie
02/03/2021
Share
Mnemo Therapeutics is a game-changing biotechnology company leveraging epigenetics to create targeted immuno-oncology treatments accessible to a broad patient population. Its approach to tackling difficult-to-treat tumours is rooted in its ground-breaking immuno-epigenetic knowledge and expertise combined with the latest developments in T cell engineering.
Laboratoire

Born from Institut Curie's incubation program, Mnemo Therapeutics is a biotech company which uses epigenetics to develop new approaches in immunotherapy. Its approach to tackling difficult-to-treat tumours is rooted in its ground-breaking immuno-epigenetic knowledge and expertise combined with the latest developments in T cell engineering.

Mnemo Therapeutics

 

 

Year of creation: 2019

Line of business: Biotechnology

Institut Curie: Incubator, institutional co-founder and R&D partner

 

TECHNOLOGY

Mnemo Therapeutics leverages epigenetic reprogramming of immune cells to improve their persistence and ability to identify tumor cells.

The company is focused on improving three key features of CAR-T cell therapy:

  • Enhancing the persistence and fitness of T cells
  • Identifying and targeting more accessible and specific cancer antigen targets
  • Bringing allogeneic treatments to patients.

 

APPLICATIONS

Immuno-oncology.